A pharmacokinetic model was constructed to explain the difference in brain-and cerebrospinal fluid (CSF)-to-plasma and brainto-CSF unbound drug concentration ratios (K p,uu,brain , K p,uu,CSF , and K p,uu,CSF/brain , respectively) of drugs under steady-state conditions in rats. The passive permeability across the blood-brain barrier (BBB), PS 1 , was predicted by two methods using log(D/molecular weight 0.5 ) for PS 1 (1) or the partition coefficient in octanol/water at pH 7.4 (LogD), topologic van der Waals polar surface area, and van der Waals surface area of the basic atoms for PS 1 (2). The coefficients of each parameter were determined using previously reported in situ rat BBB permeability. Active transport of drugs by P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) measured in P-gp-and Bcrp-overexpressing cells was extrapolated to in vivo by introducing scaling factors. Brain-and CSF-toplasma unbound concentration ratios (K p,uu,brain and K p,uu,CSF , respectively) of 19 compounds, including P-gp and Bcrp substrates (daidzein, dantrolene, flavopiridol, genistein, loperamide, quinidine, and verapamil), were simultaneously fitted to the equations in a three-compartment model comprising blood, brain, and CSF compartments. The calculated K p,uu,brain and K p,uu,CSF of 17 compounds were within a factor of three of experimental values. K p,uu,CSF values of genistein and loperamide were outliers of the prediction, and K p,uu,brain of dantrolene also became an outlier when PS 1 (2) was used. K p,uu,CSF/brain of the 19 compounds was within a factor of three of experimental values. In conclusion, the K p,uu,CSF/brain of drugs, including P-gp and Bcrp substrates, could be successfully explained by a kinetic model using scaling factors combined with in vitro evaluation of P-gp and Bcrp activities.
Introduction
For drugs acting in the central nervous system (CNS), it is assumed that an unbound drug in the brain (C u,brain ) is available to interact with the target site in the CNS. Estimating or measuring the C u,brain of new chemical entities is a critical issue in drug discovery and development to allow understanding of the relationship between drug exposure and CNS effects. However, direct measurement of C u,brain is not practicable, particularly in nonhuman primates and humans, because of its invasiveness, and thus there are great efforts to identify a surrogate. It is accepted that the unbound drug concentration in plasma (C u,p ) is not necessarily a surrogate of C u,brain (Kalvass and Maurer, 2002; Maurer et al., 2005; Liu et al., 2009; Watson et al., 2009 ) because of the bloodbrain barrier (BBB). The BBB, which is formed by endothelial cells, limits the rapid and free exchange of drugs between the CNS and blood because of the highly developed tight junctions between adjacent endothelial cells (de Lange and Danhof, 2002; Abbott, 2004) and also of the active efflux mediated by P-glycoprotein (P-gp/MDR1/ABCB1), breast cancer resistance protein (Bcrp/ABCG2), and multidrug resistance-associated protein 4 (MRP4/ABCC4) (Schinkel, 1999; Leggas et al., 2004; Belinsky et al., 2007; Enokizono et al., 2007 Enokizono et al., , 2008 Ose et al., 2009) . In fact, the C brain of drugs, and consequently the C u,brain , is inversely correlated with the activity of P-gp (Kikuchi et al., 2013) .
Drug concentration in the cerebrospinal fluid (CSF) (C u,CSF ) has been considered as a surrogate of C u,brain because the ependymal layer between CSF and CNS has been considered to allow the free exchange of drugs (Lin, 2008; Liu X et al., 2009) . CSF is produced by the choroid plexus in the ventricles, slowly turns over by bulk flow with poor mixing, and is finally absorbed into the venous blood. The choroid plexus is referred to as the blood-CSF barrier (BCSFB) because of its highly developed tight junctions between epithelial cells (Abbott, 2005) . Expression levels of P-gp and Bcrp were also detected in the choroid epithelial cells; however, their localization in these cells is suggested to be cytoplasmic or subapical for P-gp and in the brushborder membrane for Bcrp (Rao et al., 1999; Zhuang et al., 2006; Gazzin et al., 2008) . Because of the lack of P-gp and Bcrp in the blood-facing plasma membrane of the choroid epithelial cells, their substrates should easily penetrate into the CSF. Indeed, we reported that the C u,CSF of P-gp and Bcrp substrates exceeds the C u,brain in rodents, and defects in P-gp and Bcrp expression diminished this concentration difference for P-gp and Bcrp substrates, respectively (Kodaira et al., 2011) . Recently, a group of drugs were found to undergo active efflux at the BBB mediated by both P-gp and Bcrp (Oostendorp et al., 2009; Kusuhara and Sugiyama, 2009; Kodaira et al., 2010) . Simultaneous defects in P-gp and Bcrp expression are necessary to completely eliminate the concentration difference of such dual substrates (Kodaira et al., 2011) . Thus, active efflux at the BBB affects the estimation of C u,brain using C u,CSF . In addition, the C u,CSF of drugs is determined by multiple parameters, passive permeability across the BBB and BCSFB, CSF bulk flow rate, and diffusion across the ependymal layer. For quantitative interpretation of the relationship between C u,brain and C u,CSF , these factors must also be considered.
The purpose of the present study was to develop a pharmacokinetic model to describe the CSF-and brain-to-plasma and CSF-to-brain unbound concentration ratios (K p,uu,brain , K p,uu,CSF , and K p,uu,CSF/brain , respectively) in rats of 19 drugs, including P-gp and Bcrp substrates, which we had determined previously under steady-state conditions (Kodaira et al., 2011) . A nonlinear least-squares method was used to simultaneously fit the equations representing K p,uu,brain and K p,uu,CSF of drugs, including P-gp and Bcrp substrates to the observed data. We could reasonably well explain the observed K p,uu,brain and K p,uu,CSF for 17 compounds and the observed K p,uu,CSF/brain for 19 compounds in rats using the fitted parameters.
Materials and Methods
Drug Selection and Animal Data. The unbound concentrations in the brain, CSF, and plasma were calculated as the product of unbound fraction and total concentration. K p,uu,brain and K p,uu,CSF represent the C u,brain and C u,CSF divided by the C u,p , whereas K p,uu,CSF/brain represents the C u,brain divided by the C u,CSF . All these values were based on our previous report (Kodaira et al., 2011) . Of 25 compounds, 19 were selected for further analysis: benzylpenicillin, cephalexin, and cimetidine were excluded because they are substrates of organic anion transporter 3 and peptide transporter 2; sulpiride was excluded because of its low K p,uu,brain and K p,uu,CSF in rats (0.02 and 0.05, respectively); and fleroxacin and pefloxacin, which are a Bcrp-specific substrate and a dual substrate of P-gp and Bcrp, respectively, were excluded because of the uncertain involvement of Bcrp on their brain distribution in vivo.
Prediction of the BBB Passive Permeability by In Silico Structure Descriptors. BBB passive permeabilities of 19 compounds were calculated using in silico models. Based on reports by Murakami et al. (2000) and Liu et al. (2004) , a linear regression of reported logPS 1 against log(D/MW 0.5 ) or threestructure descriptors [logD, topologic van der Waals polar surface area (TPSA), and van der Waals surface area of the basic atoms (vsa_base)] for non-P-gp and non-Bcrp substrates was used in this study. PS 1 is the passive permeability clearance at the BBB (ml/s per gram), MW is the molecular weight, LogD is the partition coefficient in octanol/water at pH 7.4, TPSA is the topologic van der Waals polar surface area, and vsa_base is the van der Waals surface area of the basic atoms (Ertl et al., 2000) . The coefficients of equations in two linear regression models were calculated by regression analysis of the reported BBB permeability of non-P-gp and non-Bcrp substrate compounds (Table 1 ). The PS values observed at the BBB (observed PS 1 ) in rats were obtained by Liu et al. (2004) and Summerfield et al. (2007) . Physicochemical parameters, logD, and TPSA for the test compounds were obtained using ACD/PhysChem Suite (version 12; ACD/Laboratories, Toronto, Canada), and vsa_base was obtained using MOE 2010 (Chemical Computing Group, Montreal, QC, Canada). The PS 1 calculated by using log (D/MW 0.5 ) or three-structure descriptors was expressed as PS 1 (1) and PS 1 (2), which were corrected for brain weight per body weight in rats (1.8 g/0.25 kg) (Davies and Morris, 1993) .
Mass-Balance Differential Equations. A three-compartment model comprising the blood, brain interstitial, and CSF compartments is shown in Fig. 1 . The mass-balance equations for each compartment are shown in eq. 1, eq. 2, and eq. 3:
Blood:
Brain:
CSF:
The parameters are summarized in Table 2 . CL and k inf represent the total body clearance and infusion rate, respectively. Under steady-state conditions, K p,uu,brain and K p,uu,CSF are given by eq. 4 and eq. 5:
The drug concentration in arterial blood could be assumed to be the same as that in brain capillary blood because of the negligible extraction rate in the
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Exchange across the ependymal surface occurs along with the concentration gradient by passive diffusion. The diffusion coefficient of each compound in water is inversely proportional to the one-half power of the molecular weight (Nugent and Jain, 1984) . Therefore, PS 2 was assumed to be inversely proportional to the one-half power of the molecular weight:
where D is the fitting parameter. PS 4 is expressed using in vitro P-gp and Bcrp transport activities as follows:
where B and C represent the scaling factor for extrapolation of in vitro P-gpand Bcrp-mediated efflux activities to the corresponding in vivo parameters. Corrected flux ratio (CFR) represents the ratio of the basal-to-apical and apicalto-basal transport across the monolayers of epithelial cells expressing either P-gp or Bcrp divided by the corresponding ratio in mock-vector transfected cells, as determined previously (Kodaira et al., 2011) . CFR values that showed statistical significance were included in the calculation; otherwise, CFR was regarded as 1. By substituting eq. 6, eq. 7, and eq. 8 into eq. 4 and eq. 5, we obtained the following:
where A-D are fitting parameters. Equations 9 and 10 were simultaneously fitted to the observed data (K p,uu,brain and K p,uu,CSF ) of 19 compounds in rats using a nonlinear least-squares method (WinNonlin, version 5.2.1; Pharsight Corporation, Mountain View, CA) to obtain parameters A-D. K p,uu,CSF/brain TABLE 1 Physicochemical parameters to predict passive blood-brain barrier (BBB) permeability and in vitro transport activities of (breast cancer resistance protein (Bcrp) and P-glycoprotein (P-gp) for 19 compounds Molecular weight (MW), the partition coefficient in octanol/water at pH 7.4 (LogD) at pH 7.4, and topologic van der Waals polar surface area (TPSA) of test compounds were obtained using ACD/ PhysChem Suite (version 12, ACD/Laboratories, Toronto, Canada). The van der Waals surface area of the basic (vsa_base) was obtained using MOE 2010 (Chemical Computing Group, Montreal, QC, Canada) . The calculation of the PS 1 (1) and PS 1 (2) of test compounds is described in Materials and Methods. Corrected flux ratio (CFR), which represents the ratio of transcellular transport in transporter-expressing and control cells, was obtained from a previous study (Kodaira et al., 2011) . CFRs that showed statistical significance were included in the calculation; otherwise, CFR was regarded as 1. PS 2 , PS 3 , and PS 4 were calculated using fitted parameters. Summerfield et al. (2007) .
Pharmacokinetic Evaluation of Predictive Performance. Predictive accuracy was assessed by comparing the predicted versus observed values of K p,uu,brain , K p,uu,CSF , and K p,uu,CSF/brain . Therefore, the predictive accuracy of each passive permeability was characterized as shown in eq. 11 by using the average fold error (AFE), which gives a measure of the extent to which a particular method underpredicts or overpredicts the observed values:
where n represents the size of the data set. In addition, the resulting absolute average fold error, which takes the absolute of plus and minus data and quantifies the magnitude of difference from the true value, was also assessed, as shown in eq. 12:
The specific fold error of the deviation between the predicted and observed values was also calculated. Therefore, the percentage and number of drugs with a deviation less than 2-fold error and 3-fold error are presented for each method.
Precision was assessed based on the root mean squared error, shown in eq. 13, as follows:
To measure the degree to which the predicted and observed values are correlated, the correlation coefficient (r) was determined. The corresponding plots of predicted versus observed values are presented for each prediction method.
Statistical Analysis. Values are all presented as mean 6 S.E.M. All statistical calculations were performed using SAS software (version 9; SAS Institute, Cary, NC).
Results
In Vitro and In Vivo Parameters of 19 Compounds. The K p,uu,brain , K p,uu,CSF , and K p,uu,CSF/brain of the 19 compounds ranged from 0.00886 to 2.19, from 0.0376 to 1.35, and from 0.139 to 4.16, respectively. The K p,uu,CSF of P-gp substrates (loperamide, quinidine, and verapamil), Bcrp substrates (genistein, dantrolene, and daidzein), and a P-gp and Bcrp dual substrate (flavopiridol) were 2-fold greater than their K p,uu,brain (i.e., K p,uu,CSF/brain . 2). A linear regression analysis of the logPS 1 values of the non-P-gp and non-BCRP substrates in present study yielded two linear equations (eq. 14 and eq. 15) that contain the descriptors described in Materials and Methods. The passive permeability clearances at the BBB [PS 1 (1) and PS 1 (2)] for 19 compounds, which were calculated by two equations, ranged from 2.84 to 17.2 ml/min per kilogram and from 1.80 to 31.6 ml/min per kilogram, respectively (Table 1) . PS 1 (1) showed a positive TABLE 2 List of parameters used to describe the disposition of test compounds in the brain and cerebrospinal fluid (CSF) Eqs. 1-3 were solved under steady-state conditions to obtain K p,uu,brain (eq. 4) and K p,uu, CSF (eq. 5). PS 3 was substituted for PS 1 divided by A. B and C were defined as the in vitro-in vivo scaling factors for P-glycoprotein (P-gp)-and breast cancer resistance protein (Bcrp)-mediated efflux at the BBB. Parameters A-D were obtained by simultaneously fitting the observed K p,uu,brain and K p,uu,CSF of test compounds to eqs. 9 and 1 using a nonlinear least squares method (WinNonlin, version 5.2.1, Pharsight). Clearance for exchange across the ependymal layer PS 3 Passive clearance in the BCSFB PS 4 Active efflux in the BBB CL bulk flow Bulk flow rate (0.0029) (Suzuki et al., 1985 V 3 , volumes of the brain capillary lumen, brain, and ventricles; f blood , f u,brain , f u,CSF , unbound fraction in blood, brain, and CSF; PS 1 , PS product for passive permeability at the BBB; PS 2 , diffusion between brain and CSF; PS 3 , the PS product for passive permeability at blood-CSF barrier; PS 4 , the PS product for P-gp-and/or Bcrpmediated efflux from brain to blood; CL bulk flow , bulk flow rate of CSF; k inf , infusion rate; CL, total clearance of unbound drug.
Parameters

Concentration
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correlation with PS 1 (2), although the absolute value of PS 1 (1) was somewhat greater than that of PS 1 (2). With the exception of some outliers, both PS 1 (1) and PS 1 (2) were comparable with the observed BBB permeability; PS 1 (1) overestimated the BBB permeability of phenytoin and quinidine and underestimated that of sertraline, whereas PS 1 (2) overestimated the BBB permeability of quinidine. Determination of the Parameters A-D to Describe K p,uu,brain and K p,uu,CSF of the Test Compounds. Simultaneous fitting of K p,uu,brain and K p,uu,CSF of the 19 compounds with PS 1 obtained by two methods was performed to obtain the parameters A-D. The resulting fitted parameters A, B, C, and D were 1760 6 630 (CV: 35.6%), 7.49 6 1.68 (CV: 22.4%), 12.8 6 3.6 (CV: 28.1%), and 0.379 6 0.200 (CV: 52.7%), respectively, when PS 1 (1) was used and 1060 6 310 (CV: 37.9%), 7.48 6 1.73 (CV: 23.1%), 11.7 6 3.3 (CV: 28.4%), and 0.376 6 0.218 (CV: 58.1%), respectively, when PS 1 (2) was used. The method of calculation of PS 1 had no marked effect on the fitted parameters B-D. Parameter A determined by PS 1 (1) was 1.7 times higher than that determined by PS 1 (2).
The correlations between the predicted and observed K p,uu values are shown in Fig. 2 . Comparative assessment was conducted based on the number of compounds that fell within 2-to 3-fold error and on statistical indexes (Table 3 ). The numbers of compounds exhibiting an error less than 2-fold for K p,uu,brain and K p,uu,CSF were comparable regardless of PS 1 , whereas that for K p,uu,CSF/brain with PS 1 (1) was higher than that with PS 1 (2). There were outliers: PS 1 (1) K p,uu,CSF of genistein and loperamide (the observed and predicted values were 0.589 and 0.155 for genistein and 0.038 and 0.245 for loperamide, respectively); PS 1 (2) K p,uu,brain of dantrolene (the observed and predicted values are 0.030 and 0.095, respectively), K p,uu,CSF of genistein and loperamide (the observed and predicted values are 0.589 and 0.130 for genistein, and 0.038 and 0.271 for loperamide, respectively). Absolute average fold error and root mean squared error were slightly lower when PS 1 (1) was used for fitting (Table 3) .
Discussion
In the present study, we aimed to demonstrate that a pharmacokinetic model comprising the three compartments-brain, CSF, and plasma-is able to explain the K p,uu,brain and K p,uu,CSF of drugs and their ratio, including those of P-gp and Bcrp substrates that undergo significant active efflux by P-gp and Bcrp at the BBB, by using scaling factors for P-gp and Bcrp.
PS 1 was calculated for 19 compounds using in silico structure descriptors (Table 1) . Of the two methods tested, PS 1 (2) provided a better prediction than PS 1 (1). This was identical to the result of Liu et al. (2004) , and PS 1 (2) could reproduce the actual BBB passive permeability for all tested drugs except quinidine. Because P-gp has limited penetration to the CNS across the BBB (Kusuhara et al., 1997) , it is reasonable that quinidine was an outlier. In contrast to quinidine, both methods predicted similar or slightly lower passive permeability of risperidone, another P-gp substrate, compared with that observed. This finding is inconsistent with the observations that the brain penetration of risperidone at the BBB is also limited by P-gp (Doran et al., 2005) and that P-gp impacts on BBB permeability. Further studies are necessary to explain this discrepancy.
K p,uu,brain and K p,uu,CSF , and consequently K p,uu,brain/CSF , could be explained well using the fitted parameters. Only a small difference was found in the predictive performance of PS 1 (1) and PS 1 (2) ( Table 3 ). This result may be partly because the K p,uu,brain and K p,uu,CSF determined under steady-state conditions were used for the calculations. When transcellular transport across the BBB occurs by passive diffusion, the K p,uu,brain should be 1, irrespective of PS 1 value. For K p,uu,CSF , the difference between (K p,uu,brain , K p,uu,CSF , K p,uu,CSF/brain ) of 19 compounds in rats. The predicted K p,uu,brain and K p,uu,CSF values were obtained by simultaneously fitting the observed K p,uu,brain and K p,uu,CSF of 19 compounds in rats to eqs. 9 and 10 using a nonlinear least-squares method (WinNonlin, version 5.2.1 Pharsight) for PS 1 (1) (A) and PS 1 (2) (B). Predicted K p,uu,CSF/brain values were calculated as K p,uu,CSF divided by K p,uu,brain . Predicted values of K p,uu,brain , K p,uu,CSF , and K p,uu,CSF/brain were compared with observed values, respectively. The solid line indicates unity. Dashed lines on either side of the unity line represent factors of 2-and 3-fold, respectively. 1, antipyrine; 2, buspirone; 3, caffeine; 4, carbamazepine; 5, citalopram; 6, daidzein; 7, dantrolene; 8, diazepam; 9, flavopiridol; 10, genistein; 11, loperamid; 12, midazolam; 13, phenytoin; 14, quinidine; 15, risperidone; 16, sertraline; 17, thiopental; 18, verapamil; 19, zolpidem. Pharmacokinetic Model for Drug Disposition in the Brain 987 at ASPET Journals on August 27, 2017 dmd.aspetjournals.org PS 1 (1) and PS 1 (2) could be compensated by parameter A, which represents the difference between the BBB and BCSFB in the clearance for passive transport. Assuming an equal passive permeability per unit surface area across the BBB and BCSFB, parameter A corresponds to the difference in the surface area for drug penetration from the blood circulation into the brain and CSF. The surface area of capillaries at the BBB is 5000-fold larger than that at the BCSFB (Pardridge et al., 1981; De Lange, 2004; Reichel, 2006) . It was also reported that it is only 2-to 6-fold larger than the apical and basal surface areas, respectively, of the choroid plexus in rats (Keep and Jones, 1990) . The fitted parameter A was of the same order of magnitude as the reported value (Pardridge et al., 1981; De Lange, 2004; Reichel, 2006) . The method used for estimating PS 1 barely affected the fitted parameters B, C, and D. To verify parameters B and C, scaling factors for P-gp-and Bcrp-mediated efflux, in vivo PS P-gp and PS Bcrp of flavopiridol, the brain penetration of which is limited by both P-gp and Bcrp, were calculated using the in vitro CFR transport activities of P-gp and Bcrp, and fitted parameters B and C. In vivo PS P-gp was 4.3-fold higher than PS Bcrp . This value is almost identical to the observed value (3.3) (Kodaira et al., 2010) , which was calculated by comparing the K p,brain of flavopiridol in P-gp(-/-), Bcrp(-/-), and P-gp/ Bcrp(-/-) mice.
To explain why the K p,uu,CSF of P-gp and Bcrp substrates was lower than that of nonsubstrate drugs (Fig. 2) , despite the absence of P-gp and Bcrp in the blood-facing plasma membrane of the choroid epithelial cells (Rao et al., 1999; Zhuang et al., 2006; Gazzin et al., 2008) , PS 2 needs to be greater than PS 3 and CL bulk flow , making a significant contribution of diffusion across the ependymal surface, followed by active efflux at the BBB to the clearance pathway from the CSF (Table 1) . PS 2 was on average 5-fold greater than PS 3 , ranging from 1.96 to 17 and from 0.72 to 12 when PS 1 (1) and PS 1 (2), respectively, were used. Therefore, K p,uu,CSF does not decrease as much as K p,uu,brain with an increase in the active efflux at the BBB. Indeed, the K p,uu,CSF of P-gp and Bcrp substrates was larger than the K p,uu,brain (Kodaira et al., 2011) . The observation that the PS 2 of most compounds was above their PS 3 and CL bulk flow (Table 3) provides a rationale for using K p,uu,CSF as a surrogate of K p,uu,brain , although the magnitude of the overestimation of K p,uu,brain increases with increasing active efflux clearance. Genistein and loperamide were outliers for the prediction of K p,uu,CSF irrespective of PS 1 . K p,uu,CSF of loperamide was overestimated, whereas that of genistein was underestimated. The K p,uu,brain of loperamide was also overestimated, although it was within a 3-fold error (Fig. 2) . Because eq. 4 and 5 were obtained under steady-state conditions, insufficient duration is one explanation for the overestimation. The observations that the uptake of loperamide by brain slices did not reach a plateau, even after an 8-hour incubation in vitro (Kodaira et al., 2011) , also suggests that the brain and CSF concentrations of loperamide did not reach a plateau during a 120-minute infusion. On the other hand, the reason for the underestimation of the K p,uu,CSF of genistein is unclear. Defective expression of Bcrp diminished the difference in the unbound concentration between the brain and CSF, indicating that active efflux by Bcrp at the BBB is the predominant mechanism producing the difference in the K p,uu,brain and K p,uu,CSF (Kodaira et al., 2011) . Bcrp-mediated efflux of genistein at the BBB may be overestimated for an unknown reason.
The K p,uu,CSF/brain values of the test compounds varied from 0.24 to 2.2, showing a 10-fold difference in the mouse (Kodaira et al., 2011) , which is mainly the result of the active efflux at the BBB. The present study demonstrated that in vitro to in vivo extrapolation of the active efflux at the BBB successfully predicted this parameter, even for a P-gp and Bcrp dual substrate, using a simple pharmacokinetic model and in silico prediction of PS 1 . Once we have determined the in vitro transport activities of investigational substrates of P-gp and Bcrp, our approach will help in the estimation of the K p,uu,brain of these investigational drugs and inform the decision to use CSF concentration as a surrogate for drug development. It should be noted that the scaling factors determined in this study obviously depend on the cell lines that were used for the evaluation of P-gp and Bcrp activities. To ensure the predictability, in addition to the compounds of interest, it is strongly recommended that some P-gp-and Bcrp-specific substrates be measured as positive controls in the cell lines used in the analysis for correction of the CFR. The our approach will elucidate the relationship between C u,brain and C u, CSF in nonhuman primates and humans once we are able to determine the scaling factors for P-gp and Bcrp in humans by accumulating positron emission tomography data or by using quantitative proteomics, an emerging technique for quantifying protein expression. This will in the future improve the predictability of K p,uu,brain and K p,uu,CSF even for P-gp and BCRP substrates, although our approach will be needed to validate K p,uu values calculated by the model in humans by comparing the calculated data with in vivo data determined by PET.
In conclusion, a simple pharmacokinetic model that includes active efflux transport at the BBB can reasonably describe the K p,uu,CSF/brain of drugs, even including P-gp and Bcrp substrates, by introducing in vitro and in vivo scaling factors for P-gp and Bcrp.
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